Peter Cornell, MD
Ophthalmology · Beverly Hills, CANPI 1548370794
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 44.4% of the total. Reporting peaked in 2023 at $10,836 and has fallen 82.0% since, to $1,953 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $125.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$11K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$9K
- Alcon Research LLC$1K
- Alcon$372
- Kala Pharmaceuticals, Inc.$256
- Tarsus Pharmaceuticals, Inc.$246
- plus $2K from 23 others
Across 2 payments — averaging $689.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$1K
What the payments were for
- Consulting fees$10,90045%
- Speaking & faculty fees$8,40035%
- Travel & lodging$360%
- Food & beverage$4,73320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 31 | $10,695 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $9,145 |
| Alcon Research LLC | 2 | $1,100 |
| Alcon | 17 | $372 |
| Kala Pharmaceuticals, Inc. | 16 | $256 |
| Tarsus Pharmaceuticals, Inc. | 9 | $246 |
| Oyster Point Pharma, Inc. | 10 | $219 |
| Sun Pharmaceutical Industries Inc. | 10 | $204 |
| AbbVie(2 entities) | 10 | $198 |
| Johnson & Johnson Vision Care, Inc. | 7 | $194 |
| Amgen(2 entities) | 8 | $176 |
| Glaukos Corporation | 3 | $170 |
| Eyevance Pharmaceuticals LLC | 8 | $168 |
| Novartis | 6 | $145 |
| Thea Pharma Inc. | 5 | $118 |
| Akorn Operating Company LLC | 6 | $112 |
| Dompe US, Inc. | 3 | $97 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $62 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Harrow Eye, LLC | 2 | $59 |
| Ocular Therapeutix, Inc. | 3 | $58 |
| Stryker | 1 | $52 |
| LKC Technologies, Inc. | 1 | $38 |
| Omeros Corporation | 2 | $31 |
| Optos, Inc. | 1 | $22 |
| Rxsight Inc | 1 | $21 |
| Staar Surgical Company | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Quidel Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$9,925
- enVista MX60 IOL$9,925
- Trulign IOL$9,925
- Crystalens Accommodating IOL (AT-52AO)$9,925
- STELLARIS PC$8,538
- CRYSTALENS$8,538
- AKREOS AO$8,538
- ENVISTA$8,538
- TRULIGN TORIC$8,538
- Unity$1,100
- iStent inject Trabecular Micro-Bypass Stent System$123
How this compares
$24,069 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 134 | $155,417 |
| XdemvyLotilaner | 42 | $77,878 |
| LumiganBimatoprost | 114 | $59,273 |
| RocklatanNetarsudil Mesylat/Latanoprost | 95 | $46,378 |
| Alphagan PBrimonidine Tartrate | 52 | $32,893 |
| VyzultaLatanoprostene Bunod | 57 | $28,257 |
| XiidraLifitegrast | 26 | $25,760 |
| Restasis MultidoseCyclosporine | 25 | $18,487 |
| CombiganBrimonidine Tartrate/Timolol | 40 | $15,585 |
| Brimonidine Tartrate | 91 | $14,643 |
| MieboPerfluorohexyloctane/Pf | 15 | $14,570 |
| RhopressaNetarsudil Mesylate | 26 | $12,883 |
| TyrvayaVarenicline Tartrate | 17 | $10,926 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 37 | $8,084 |
| AzoptBrinzolamide | 17 | $7,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Restasis Multidose, Combigan | $198 | $281,656365 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $246 | $77,87842 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $10,695 | $68,58798 claims |
| AlconAzopt, Simbrinza | $372 | $13,62337 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $219 | $10,92617 claims |
| NovartisTravatan Z | $145 | $6,70415 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $9,145 | $6,58921 claims |
| Eyevance Pharmaceuticals LLCFlarex | $168 | $2,28218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Beverly Hills
- Raymond DouglasBeverly Hills$1.3M
- Stuart StollBeverly Hills$673K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.